mFOLFOX6+bevacizumab + PD-1 monoclonal antibody in locally advanced MSS CRC (BASKETII): A prospective, single-arm, open-label, phase II study

被引：0
|
作者：
Huang, J. [1 ]
He, W. [2 ]
Zhao, Y. [3 ]
He, F. [4 ]
Liu, Z. [5 ]
Pei, F. [6 ]
Yao, Q. [7 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Colorectal Surg, Guangzhou, Peoples R China
[2] Jinan Univ, Shenzhen Peoples Hosp, Oncol Dept, Shenzhen, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 6, Radiotherapy, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 6, Coloproctol, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2024.10.096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1433 / S1433
页数：1
相关论文
共 50 条
  • [21] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Zhao, Shuangshuang
    Zhang, Minmin
    Zhang, Qing
    Wu, Jingjun
    Dai, Hui
    BMC CANCER, 2024, 24 (01)
  • [22] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Shuangshuang Zhao
    Minmin Zhang
    Qing Zhang
    Jingjun Wu
    Hui Dai
    BMC Cancer, 24
  • [23] PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial
    Sun, Yu-Ting
    Guan, Wen-Long
    Zhao, Qi
    Wang, De-Shen
    Lu, Shi-Xun
    He, Cai-Yun
    Chen, Shuang-Zhen
    Wang, Feng-Hua
    Li, Yu-Hong
    Zhou, Zhi-Wei
    Xu, Rui-Hua
    Qiu, Miao-Zhen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (10): : 5006 - +
  • [24] Efficacy and Safety of Lenalidomide, PD-1 Monoclonal Antibodies Combined with Orelabrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase II Study
    Wang, Lingling
    Huang, Yongfen
    Chen, Hui
    Xu, Hao
    Cheng, Yuexin
    Miao, Yuqing
    BLOOD, 2024, 144 : 6488 - 6489
  • [25] Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera
    Karapetis, Christos S.
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    Fischer, JuDee
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 156 - 163
  • [26] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera A.
    Karapetis, Christos Stelios
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study
    Zhao, M.
    Liu, X.
    Yuan, C.
    Zheng, W.
    Zhang, D.
    Long, Q.
    Li, J.
    Han, T.
    Xu, L.
    Li, H.
    Li, X.
    Shi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S36 - S37
  • [28] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [29] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [30] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
12345